GET DAILY SIGNALSTravere Therapeutics (TVTX): What to Watch as Q3 2026 Earnings Approach
Key Takeaways
- Travere Therapeutics (TVTX) is expected to report third quarter 2026 results in late October to early November, after the market close.
- Consensus estimates point to revenue of roughly $198 million, with earnings per share near breakeven — ranging from a small loss to a modest profit depending on the source.
- FILSPARI (sparsentan), the company's lead rare kidney disease drug, remains the core growth driver across its IgA nephropathy (IgAN) and newly launched focal segmental glomerulosclerosis (FSGS) indications.
- Last quarter, TVTX beat revenue expectations but missed on earnings per share; shares still rallied on record FILSPARI demand and a strong FSGS launch.
- Investors will watch patient start forms, gross-to-net pricing dynamics, and progress on the Phase III HARMONY study of pegtibatinase.
Earnings Context and Why It Matters
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, and its growth story now revolves almost entirely around FILSPARI. The drug is approved for IgA nephropathy (a chronic kidney condition) and, more recently, for FSGS — a launch that began generating revenue almost immediately. That commercial momentum makes each quarterly print a key signal for investors. In the second quarter of 2026, the company reported total revenue of about $169.6 million, beating consensus, with FILSPARI sales surging roughly 96% year over year. The upcoming third quarter report will test whether that demand is sustainable and whether the FSGS launch continues to scale ahead of expectations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
For the third quarter of 2026, Wall Street expects Travere Therapeutics to report revenue of approximately $198 million, according to consensus estimates. On the bottom line, forecasts are clustered near breakeven, with analysts projecting results ranging from a small loss to a modest profit per share — reflecting the company's transition toward profitability as FILSPARI sales expand.
Revenue growth will again be driven primarily by FILSPARI net product sales. In the second quarter, FILSPARI generated about $141.1 million in U.S. sales on record demand, with more than 2,000 new patient start forms across IgA nephropathy and FSGS. Management has also flagged that gross-to-net discounts are expected to remain in the mid-20% range for 2026, a metric investors should watch closely for any impact on realized pricing.
Beyond the headline numbers, the market will focus on FSGS launch trajectory, patient start form counts, and any updates to full-year guidance. Historically, TVTX shares have reacted sharply to demand-related news rather than bottom-line beats alone, making the commercial metrics at least as important as the earnings per share figure.
Market Reaction and Investor Sentiment
Sentiment heading into the third quarter report is broadly constructive. Following the second quarter release in August 2026, shares rose sharply as investors rewarded record FILSPARI demand and the early strength of the FSGS launch, even though earnings per share came in below consensus. That reaction underscores a key dynamic: the market is primarily valuing TVTX on its commercial growth trajectory rather than near-term profitability.
Still, risks remain. The stock has been volatile around earnings in the past, and any sign of slowing patient starts, softer-than-expected FSGS uptake, or heavier gross-to-net discounts could weigh on sentiment. Conversely, continued demand momentum and a reaffirmed peak sales target for FILSPARI could support further optimism.
Forward Outlook and Key Factors to Monitor
Looking beyond the third quarter, the central question is whether FILSPARI can sustain its dual-indication growth. In IgA nephropathy, the company continues to expand prescribing depth while navigating an increasingly competitive treatment landscape. In FSGS, early launch metrics have outpaced the initial IgA nephropathy rollout, but management has cautioned that a single quarter is not enough to extrapolate long-term trends.
Investors should also monitor the broader pipeline. The Phase III HARMONY study of pegtibatinase, a potential disease-modifying therapy for classical homocystinuria (HCU), is actively enrolling, with results anticipated in the second half of 2027. Additionally, the company recently expanded its rare kidney disease portfolio through an exclusive licensing agreement for civorebrutinib, adding an upstream immune-modulating approach with potential across multiple immune-mediated kidney diseases.
On the financial side, watch for updates on cash position, operating expense trends, and any commentary on the company's recent convertible notes refinancing. Research and development spending may remain elevated as the HARMONY study progresses, while selling, general, and administrative costs reflect the expanded commercial field team supporting the FSGS launch. These factors will shape the path toward sustained profitability. From what I see, the commercial execution on FILSPARI remains the dominant driver here.
Refining My Earnings Watchlist with AI Tools
In my own process for preparing for earnings season, I often turn to Tickeron’s AI Screener. It helps me quickly scan for stocks showing notable technical setups or fundamental momentum ahead of reports like this one, giving additional context on how TVTX stacks up against peers without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TVTX's RSI Indicator recovers from oversold territory
The RSI Indicator for TVTX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 24 of the 27 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 61 cases where TVTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in 217 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
TVTX moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TVTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for TVTX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TVTX's P/B Ratio (238.095) is very high in comparison to the industry average of (2.988). P/E Ratio (17.370) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (5.690) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops pharmaceutical products
Industry Biotechnology
Advertisement